Peginterferon alfa-2a
- Generic Name
- Peginterferon alfa-2a
- Brand Names
- Pegasys
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 198153-51-4
- Unique Ingredient Identifier
- Q46947FE7K
- Background
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting...
- Indication
Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease . May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
...
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, HBeAg Positive Chronic Hepatitis B
- Associated Therapies
- -
Lonafarnib With and Without Ritonavir in HDV (LOWR-1)
- Conditions
- Interventions
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Eiger BioPharmaceuticals
- Target Recruit Count
- 21
- Registration Number
- NCT02430181
- Locations
- 🇹🇷
Ankara University Medical School, Ankara, Turkey
Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment
- First Posted Date
- 2015-02-18
- Last Posted Date
- 2019-09-04
- Target Recruit Count
- 14
- Registration Number
- NCT02364336
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase
- Conditions
- Interventions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 62
- Registration Number
- NCT02263079
- Locations
- 🇧🇪
Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇮🇹Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi; U.O. Malattie Infettive, Bologna, Emilia-Romagna, Italy
🇩🇪Universitätsklinikum Essen; Klinik für Kinder- und Jugendmedizin Pädiatrie II, Essen, Germany
An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT02201407
- Locations
- 🇷🇸
Clinical Center Zemun, Belgrade, Serbia
🇷🇸Clinic for Gastroenterology and Hepatology, Belgrade, Serbia
🇷🇸Clinical Center Vojvodine; Clinic for Infectious Diseases; Clinic for Hematology, Novi Sad, Serbia
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 158
- Registration Number
- NCT02174172
- Locations
- 🇺🇸
HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)
- Conditions
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 60
- Registration Number
- NCT02107365
- Locations
- 🇫🇷
Hôpital Jean Verdier, Bondy, France
🇫🇷Hôpital de Haut Lévêque, Bordeaux Pessac, France
🇫🇷Hôpital Beaujon, Clichy, France
Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)
- Conditions
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10228
- Registration Number
- NCT02106156
Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Markus Peck-Radosavljevic
- Target Recruit Count
- 6
- Registration Number
- NCT01925183
- Locations
- 🇦🇹
Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1
- Conditions
- Interventions
- First Posted Date
- 2013-07-02
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Timothy Morgan, MD
- Registration Number
- NCT01890772
- Locations
- 🇺🇸
Minneapolis VAHCS, Minneapolis, Minnesota, United States
🇺🇸VA Long Beach Healthcare System, Long Beach, California, United States
🇺🇸Kansas City VA Medical Center, Kansas City, Missouri, United States
The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)
- Conditions
- Interventions
- First Posted Date
- 2013-07-01
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- TCM Biotech International Corp.
- Registration Number
- NCT01890200
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Taoyuan, Taiwan
🇨🇳Peking University People's Hospit, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.